<DOC>
	<DOCNO>NCT00665197</DOCNO>
	<brief_summary>Hypothesis : In management advanced oesophageal cancer , determine short regime external beam radiotherapy ( use high daily dos , combine intraluminal high dose rate brachytherapy ) inferior palliation dysphagia protract course external beam radiotherapy ( use low daily dos combine equal intraluminal high dose rate brachytherapy ) .</brief_summary>
	<brief_title>Palliative Radiotherapy Brachytherapy Oesophageal Cancer Dysphagia</brief_title>
	<detailed_description>This prospective , pragmatic multi-centre clinical trial , without blind mask randomly assign treatment . Patient registration randomization centralize . There two arm study , expect equal number patient randomized arm . Stratification accord : ( 1 ) treat institution/country , ( 2 ) baseline Stage ( M1 = distant metastasis versus M0 = distant metastasis ) . The primary statistical analysis conduct `` intention-to-treat '' clinical trial . A cost-effectiveness analysis require main contrast 5 10 fraction EBRT , 5 fraction less expensive 10 fraction . This protocol follow recommendation CONSORT report non-inferiority equivalence trial . The active control 30 Gy 10 fraction , new therapy 20 Gy 5 fraction .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Endoscopic biopsyproven carcinoma esophagus , either Adenocarcinoma Squamous cell carcinoma ; Lesions thoracic oesophagus abdominal oesophagus involve cardia stomach . ( The oesophagus extend cricopharyngeus muscle level cricoid cartilage GEJ junction . The proximate cervical oesophagus extend approximately 23 cm distal cricopharyngeus muscle approximately 18 cm incisor , exclude study ; however remain oesophagus include study , include last 12 cm oesophagus intraabdominal GEJ . ) ; Dysphagia immediately prior first HDR ILBT session ( base 4question summary score 415 ( i.e . less score 16 ) use four question EORTC QLQ OES18 measure ; Able insert intraesophageal applicator ( Dilatation allow open tumor/lumen facilitate insertion , preclude eligibility . Any oesophageal stent must remove prior brachytherapy metal stent may inappropriately increase dose radiation esophageal wall approximately 10 % . ] ) ; Karnofsky 40 90 , inclusive baseline ( patient 100 least dysphagia disease baseline ; patient KPS &lt; 40 eligible study ) ; Eligible radiotherapy ( e.g . pacemaker within 2.5 cm outside field edge EBRT component therapy ) ; Signed informed consent . Age le 18 ; Patients suitable curative treatment either surgery chemoradiation ; Tracheoesophageal fistula , deep mucosal ulceration ; Perforation massive esophageal bleeding ; Previous treatment ( e.g . chemotherapy , radiation therapy , laser therapy surgery ) esophageal cancer ( gastrostomy PEG constitute exclusion criterion , consider patient complete obstruction substantial loss body weight prior diagnosis ) ; Stents situ ( i.e . remove prior first HDR ILBT ) ; Previous thoracic radiation therapy cause , either EBRT ILBT ; Evidence uncontrolled malignancy , evidence synchronous head neck lung primary cancer ( regardless whether malignancy could manage curative intent ) ; Failure complete baseline assessment require study , include patientelicited score symptom QOL ; Pregnant lactating patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Palliation</keyword>
	<keyword>Dysphagia</keyword>
</DOC>